Marie Curie Cancer Care Open Access Policy

Version 2

Audience
Researchers at Marie Curie’s Research Facilities and researchers funded through Marie Curie’s open and competitive grant funding streams.

Summary
This document outlines Marie Curie’s policy on making academic publications arising from its research funding open access, and how open access fees can be paid for.

Supporting documents
n/a

Open Access and Europe PMC

Marie Curie Cancer Care relies on donations from the public to fund its activities, including research into palliative and end of life care. Marie Curie Cancer Care is therefore committed to ensuring that the results of its research funding are available as freely and widely as possible and has made this a condition of its funding arrangements.

Electronic copies of publications arising from Marie Curie Cancer Care funding should be made available through Europe PubMed Central (Europe PMC) as soon as possible and in any event within six months of the date of publication.

Europe PMC is a permanent and free to access digital archive of biomedical and life sciences journal literature, funded by a consortium of leading UK and European biomedical research funders, including Marie Curie Cancer Care.

The policy applies to peer-reviewed, original research publications that have been supported wholly or partly by Marie Curie Cancer Care. The policy does not apply to book chapters, editorials, reviews or conference proceedings.

Acknowledgement of Marie Curie Cancer Care funding

Authors must ensure that funding from Marie Curie Cancer Care is acknowledged in any papers published as a result of Marie Curie support. The grant reference number should be included.
Recommended wording for acknowledgement of project grant funding:

“This work was supported by the Marie Curie Cancer Care Research Programme, grant [grant reference number].”

“This work was supported by the Dimbleby Marie Curie Cancer Care Research Fund, grant [grant reference number].”

Recommended wording for acknowledgement of facility funding:

“This work was supported by Marie Curie Cancer Care core/programme grant funding to the ‘name of facility’ [grant reference number].”

“[Author]’s post(s) is/are supported by Marie Curie Cancer Care core/programme grant funding, grant [grant reference number].”

**Funding for open access publications**

**For Marie Curie Cancer Care’s open and competitive funding streams:**

Marie Curie Cancer Care will consider requests for open access publication fees (either article processing charges for fully open access journals, or fees paid to non-open access journals to make a particular article publicly available) as part of applications to all Marie Curie Cancer Care open and competitive funding streams.

Marie Curie expects all research costs, including publishing costs, to be budgeted for when a grant application is submitted, and will not fund additional publishing costs. However, unspent Marie Curie grant funds may be vired to cover open access costs for publications resulting from that project.

**For Marie Curie Cancer Care Research Centres:**

Open access fees will be paid for Marie Curie funded work where Marie Curie has been acknowledged as the sole funder. If work has additionally been funded by one or more other funding bodies, Marie Curie will pay the relevant proportion of the costs.

Authors should contact Marie Curie Cancer Care at the time of submission to a journal, to notify Marie Curie Cancer Care of the journal’s open access route and costs and to request the relevant funds.

**Guidelines on how to comply with Marie Curie Cancer Care’s Open Access Policy**

Researchers can comply with this policy through one of two routes. A manuscript may be submitted to a journal that offers an open access option. The journal will then deposit a copy of the final article in the Europe PMC database.

Researchers may, alternatively, submit manuscripts to a publisher that does not offer an open access option but does permit a copy of the research article to be deposited, and made publicly available, in Europe PMC. This may either be on publication or after an embargo period specified by the publisher. Authors should clarify with the publisher which version of the manuscript they are permitted to self-archive.

Through Europe PMC’s grant reporting service, Europe PMC plus, grant-holders who are supported by any member of the Europe PMC Funders’ Group may self-archive peer-reviewed papers that have been accepted for publication (to be used only if the journal does not offer to deposit in an open access repository on the author’s behalf), and create useful reports linking their papers to grants.

A small number of journals are non-compliant with Marie Curie Cancer Care’s open access policy. However, Marie Curie does not wish to prevent researchers from submitting research publications to the most appropriate journal, some of which may not be compliant with this policy. As a result Marie Curie funded researchers may publish in exceptional circumstances in a journal that would not allow the article to be deposited in Europe PMC within 6 months.
We will provide the names and contact details of our grant holders to Europe PMC in connection with the administration of the Europe PMC database and website. Europe PMC may contact grant holders directly.

Open access publications will be linked to Marie Curie grants on Europe PMC.

Please contact Dr Bidisha Chakraborty, Research Officer, with any questions: research.info@mariecurie.org.uk

Governance

Consultation
This policy was developed in consultation with the Association of Medical Research Charities and is the result of Marie Curie Cancer Care joining the Europe PMC (Europe PubMed Central) Funders’ Group. The policy was developed within the Research Management Team with input from the Head of the Marie Curie Palliative Care Research Unit at University College London.

References and related documents
www.europepmc.org

Document history
n/a

<table>
<thead>
<tr>
<th>Author</th>
<th>Katie Hyde</th>
<th>Research Officer</th>
<th>Aug 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified by</td>
<td>Dr Bidisha Chakraborty</td>
<td>Research Officer</td>
<td>Mar 2014</td>
</tr>
<tr>
<td>Approved by</td>
<td>Trevor Lake, Company Secretary</td>
<td></td>
<td>Aug 2012</td>
</tr>
<tr>
<td></td>
<td>Dr Sabine Best, Head of Research</td>
<td></td>
<td>Mar 2014</td>
</tr>
<tr>
<td>Ratified by</td>
<td>Dr Teresa Tate</td>
<td>Medical Adviser</td>
<td>Aug 2012</td>
</tr>
<tr>
<td></td>
<td>Dr Bill Noble</td>
<td>Medical Director</td>
<td>Mar 2014</td>
</tr>
</tbody>
</table>